Categories: News

SoftSmile Announces FDA 510(k) Clearance for AI Powered Software VISION

NEW YORK, Jan. 18, 2022 /PRNewswire/ — SoftSmile, a leading medical technology company based in NY, and developer of advanced orthodontic software solutions, announced its software device was cleared by the U.S. Food and Drug Administration (FDA) pursuant to a 510(k) pre-market notification.

“FDA clearance is a huge step for SoftSmile because it establishes Vision’s position as a leading software service.”

SoftSmile’s software VISION, an end-to-end treatment planner made by doctors for doctors, has been granted FDA clearance. This innovative, user-friendly interface gives doctors the ability to create precise aligner treatment plans which are then manufactured using advanced 3-D printing technologies. This news-worthy FDA clearance paves the road to market VISION to doctors and opens the possibility of transforming the existing orthodontic market. 

SoftSmile is currently working with established aligner manufacturers. With this FDA clearance, SoftSmile can start marketing Vision as a standalone application to be used directly by doctors.

This FDA clearance sets in motion SoftSmile’s plans to transform the market by offering doctors treatment planning software directly, which makes it possible to offer more options to patients thereby cutting costs and increasing efficiency. This development clears the way for this one of a kind innovative software solution with capabilities including but not limited to an automated segmentation feature and intuitive and comprehensive staging. The software automatically generates key aspects of a digitally optimized treatment plan.

VISION’s revolutionary technology can now be used in any practice without a doctor having to go through third party designers and/or manufacturers.

“FDA clearance is a huge step for SoftSmile because it establishes Vision’s position as a leading software service that complies with all requirements imposed by FDA and is safe for use in the medical practice. There are just a few orthodontic treatment planners that have obtained FDA clearance. SoftSmile’s new status is a groundbreaking assurance for the market because the FDA is the best quality check for doctors and patients. This achievement opens new opportunities for the company and proves that our team can solve any type of challenge. It took nearly 18 months, enormous resources, and the coordinated efforts of our engineers and lawyers to be granted FDA clearance. Fortunately, we have only the best at SoftSmile which has now been given the FDA’s stamp of approval,” said Khamzat Asabaev, Founder and CEO.  

About SoftSmile, Inc.
SoftSmile is a New York-based innovation technology company that helps orthodontists to deliver custom, high-quality, and affordable treatment to their patients. Established in 2019, SoftSmile designs and develops an advanced, AI-driven orthodontic software package that applies innovative machine learning technology with sound biomechanical and mathematical principles in a user-friendly interface, giving orthodontists the ability to create aligners treatment plans in-house. These products give orthodontists unparalleled control and precision of the treatment they deliver to their patients. SoftSmile was created by doctors, for doctors.

For additional information about VISION, Inc. please visit https://www.softsmile.com.

CONTACT: press@softsmile.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/softsmile-announces-fda-510k-clearance-for-ai-powered-software-vision-301461521.html

SOURCE SoftSmile

Staff

Recent Posts

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

9 hours ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

15 hours ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

15 hours ago

Extendicare Announces December 2025 Dividend of C$0.042 per Share

MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:…

15 hours ago

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and…

15 hours ago